# Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

> **NCT00396448** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 1253 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** CP-945,598 Treatment B
- **DRUG:** CP-945,598 Treatment A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00396448
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 1253 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396448, "Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00396448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*